25 May 16. Defence Committee, UK Military Operations In Syria And Iraq. Thursday 26 May 2016 Thatcher Room, Portcullis House.
• Rt Hon Michael Fallon MP, Secretary of State for Defence
• Lieutenant General Mark Carleton-Smith CBE, Deputy Chief of the Defence Staff (Military Strategy and Operations)
• Dominic Wilson, Director of Operational Policy, Ministry of Defence
The Committee will hold its final oral evidence session on its inquiry into UK military operations in Syria and Iraq. The Committee will question the Secretary of State for Defence on:
• the military and political strategy to counter DAESH;
• the military and political implications of the UK’s military involvement in Syria in operations against DAESH;
• the nature and capability of DAESH and Syrian Opposition; and
• the integration between Daesh in Iraq and Syria and its affiliates.
23 May 16. Lariam, the anti-malarial drug sometimes prescribed to British troops, should be considered only as a drug of last resort, says the Defence Committee, in its report, published today, on the MoD’s use of the drug.
Lariam (also known as mefloquine) has a high-risk profile and a minority of users experience severe side-effects. These side-effects are clearly highlighted by Roche, the manufacturer of Lariam, who rightly lay down stringent conditions which must be met if it is to be prescribed safely. But there is very strong anecdotal evidence that such conditions have often been disregarded in dispensing it to large numbers of troops about to be deployed.
Chairman of the Committee, Dr Julian Lewis MP, says: “It seems quite clear that not only is the MoD unable to follow the manufacturer’s guidelines for prescribing the drug in all instances, but a number of troops discard their Lariam rather than risk its potentially dangerous side-effects. It is our firm conclusion that there is neither the need, nor any justification for continuing to issue this medication to Service personnel unless they can be individually assessed, in accordance with the manufacturers’ requirements. And–––most of the time–––that is simply impossible, when a sudden, mass deployment of hundreds of troops is necessary.”
The Committee conclude that any future prescribing of Lariam to Service personnel must be restricted:
• Only to those who are unable to tolerate any of the available alternatives;
• Only after a face-to-face Individual Risk Assessment has been conducted; and
• Only after the patient has been made aware of the alternatives and has been given the choice between Lariam and another suitable anti-malarial drug.
The danger of severe side-effects from using Lariam has been highlighted by both Roche and other witnesses to the Inquiry. The evidence received has emphasised the specific risks that such side-effects can place on military personnel when deployed and the belief that the military environment has the potential to exacerbate those side-effects. While most users will not experience the most adverse reactions, the Committee does not believe Lariam, with its significant risk profile, is compatible with the duties required of military personnel on operations.
Strong anecdotal evidence suggests that a body of current and former Service personnel have been adversely affected by the use of Lariam. The MoD acknowledges its duty of care to support them, but the current arrangements for doing so appear to be inadequate. The report recommends that the MoD should establish a single point of contact for all current and former Service personnel who have concerns about their experience of Lariam. This point of contact should be publicised widely though the Chain of Command, veterans organisations, the MoD website, and armed forces magazines and publications. Discussions should also be held with the Department of Heath on possible ways of advising GPs of potential risks to veterans who may previously have been prescribed Lariam.
House of Commons and House of Lords Hansard